Global Castration Resistant Prostate Cancer Treatment Market 2017-2021

  • ID: 4328287
  • Report
  • Region: Global
  • 87 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Active Biotech
  • Astellas Pharma
  • Bayer
  • GlaxoSmithKline
  • Madrigal Pharmaceuticals
  • Northwest Biotherapeutics
  • MORE
About Castration-Resistant Prostate Cancer (CRPC) Treatment

Prostate cancer is also known as carcinoma of the prostate is cancer of the prostate gland that affects only the male population. It is a slow progressive disease. CRPC is an inveterate stage of prostate cancer, in which almost 90% of individuals develop metastases, specifically in the skeleton. The major therapies involved in the treatment of CRPC are hormonal therapy and chemotherapy.

The analysts forecast the global castration-resistant prostate cancer treatment market to grow at a CAGR of 9.01% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global castration resistant prostate cancer treatment market for 2017-2021. To calculate the market size, the report considers sales of branded, generic, and off-label drugs.

The market is divided into the following segments based on geography:
  • Americas
  • APAC
  • EMEA
The report, Global Castration-Resistant Prostate Cancer (CRPC) Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Astellas Pharma
  • Johnson & Johnson
  • Sanofi
  • Valeant
Other prominent vendors
  • Active Biotech
  • Advaxis
  • ANI Pharmaceuticals
  • Athenex
  • Bavarian Nordic
  • Bayer
  • Bristol-Myers Squibb
  • CureVac
  • GlaxoSmithKline
  • Innocrin Pharmaceutical
  • Merck
  • Myovant Sciences
  • Northwest Biotherapeutics
  • OncoGenex Pharmaceuticals
  • Oncolytics Biotech
  • Orion
  • Sotio
  • Madrigal Pharmaceuticals)
  • Takeda Pharmaceutical
  • Teva Pharmaceutical Industries
Market drivers
  • Physician’s preference toward hormonal therapy
  • For a full, detailed list, view the full report
Market challenges
  • High cost of treatment
  • For a full, detailed list, view the full report
Market trends
  • Increasing consolidation in cancer treatment market
  • For a full, detailed list, view the full report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?
You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Active Biotech
  • Astellas Pharma
  • Bayer
  • GlaxoSmithKline
  • Madrigal Pharmaceuticals
  • Northwest Biotherapeutics
  • MORE
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
  • Market outline
  • CRPC
PART 05: Market landscape
  • Market overview
  • Market size and forecast
  • Five forces analysis
PART 06: Pipeline landscape

PART 07: Market segmentation by therapy
  • Hormonal therapy
  • Chemotherapy
  • Others
PART 08: Geographical segmentation
  • CRPC treatment market in Americas
  • CRPC treatment market in EMEA
  • CRPC market in APAC
PART 09: Decision framework

PART 10: Drivers and challenges
  • Market drivers
  • Market challenges
PART 11: Market trends
  • Increasing consolidation in cancer treatment market
  • Emergence of targeted therapies and immunotherapies
PART 12: Vendor landscape
  • Competitive landscape
PART 13: Key vendor analysis
  • Astellas Pharma
  • Johnson & Johnson
  • Sanofi
  • Valeant
  • Other prominent vendors
PART 14: Appendix
  • List of abbreviations
List of Exhibits
Exhibit 01: Snapshot of prostate cancer
Exhibit 02: Types of prostate cancer
Exhibit 03: Main diagnostic procedures to determine presence of prostate cancer
Exhibit 04: Treatment options for CRPC
Exhibit 05: Drug evolution for CRPC
Exhibit 06: Treatment snapshot of CRPC
Exhibit 07: Global CRPC treatment market snapshot
Exhibit 08: Global CRPC treatment market 2016-2021 ($ millions)
Exhibit 09: Opportunity analysis in global CRPC treatment market
Exhibit 10: Five forces analysis
Exhibit 11: Key pipeline molecules by vendors
Exhibit 12: Key clinical trials
Exhibit 13: Segmentation of global CRPC treatment market by therapy 2016
Exhibit 14: Global CRPC treatment market share by therapy 2016-2021 (%)
Exhibit 15: General factors leading to the adoption of hormonal therapy
Exhibit 16: Global CRPC hormonal therapy market 2016-2021 ($ millions)
Exhibit 17: Market snapshot for CRPC hormonal therapy market 2016
Exhibit 18: Major types of chemotherapy
Exhibit 19: Global CRPC chemotherapy market 2016-2021 ($ millions)
Exhibit 20: Market snapshot for CRPC chemotherapy market 2016
Exhibit 21: Global CRPC other therapies market 2016-2021 ($ millions)
Exhibit 22: Market snapshot for global CRPC other therapies market 2016
Exhibit 23: Segmentation of global CRPC treatment market by geography 2016 and 2021
Exhibit 24: CRPC treatment market revenue by geography 2016-2021 ($ millions)
Exhibit 25: Market scenario in Americas
Exhibit 26: CRPC treatment market in Americas 2016-2021 ($ millions)
Exhibit 27: Key trends across various countries in Americas
Exhibit 28: Market scenario in EMEA
Exhibit 29: CRPC treatment market in EMEA 2016-2021 ($ millions)
Exhibit 30: Trends in prostate cancer therapeutics market in EMEA
Exhibit 31: Market scenario in APAC
Exhibit 32: CRPC treatment market in APAC 2016-2021 ($ millions)
Exhibit 33: Key drivers and challenges in APAC
Exhibit 34: Population of 65 years and above people in US 2015 and 2050 (in millions)
Exhibit 35: Global percentage of population aged 60 and above by region 2015 and 2050
Exhibit 36: Major cancer types affecting US male population (per 100,000 men)
Exhibit 37: Alternative therapies
Exhibit 38: Major side effects of CRPC drugs
Exhibit 39: Competitive structure analysis of global CRPC treatment market 2015
Exhibit 40: Astellas Pharma: Key highlights
Exhibit 41: Astellas Pharma: Strength assessment
Exhibit 42: Astellas Pharma: Strategy assessment
Exhibit 43: Astellas Pharma: Opportunity assessment
Exhibit 44: Johnson & Johnson: Key highlights
Exhibit 45: Johnson & Johnson: Strength assessment
Exhibit 46: Johnson & Johnson: Strategy assessment
Exhibit 47: Johnson & Johnson: Opportunity assessment
Exhibit 48: Sanofi: Key highlights
Exhibit 49: Sanofi: Strength assessment
Exhibit 50: Sanofi: Strategy assessment
Exhibit 51: Sanofi: Opportunity assessment
Exhibit 52: Valeant: Key highlights
Exhibit 53: Valeant: Strength assessment
Exhibit 54: Valeant: Strategy assessment
Exhibit 55: Valeant: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Active Biotech
  • Astellas Pharma
  • Bayer
  • GlaxoSmithKline
  • Madrigal Pharmaceuticals
  • Northwest Biotherapeutics
  • MORE
New Report Released: - Global Castration-Resistant Prostate Cancer (CRPC) Treatment Market 2017-2021

The author of the report recognizes the following companies as the key players in the global castration-resistant prostate cancer treatment market: Astellas Pharma, Johnson & Johnson, Sanofi, and Valeant.

Other Prominent Vendors in the market are: Active Biotech, Advaxis, ANI Pharmaceuticals, Athenex, Bavarian Nordic, Bayer, Bristol-Myers Squibb, CureVac, GlaxoSmithKline, Innocrin Pharmaceutical, Merck, Myovant Sciences, Northwest Biotherapeutics, OncoGenex Pharmaceuticals, Oncolytics Biotech, Orion, Sotio, Madrigal Pharmaceuticals), Takeda Pharmaceutical, and Teva Pharmaceutical Industries.

Commenting on the report, an analyst from the research team said: “One trend in the market is increasing consolidation in cancer treatment market. The oncology drugs industry has seen significant R&D and funding, which are largely responsible for the increasing consolidation of the industry. The rising trend of movement of cancer treatment from clinics to hospitals signifies the growing importance of strategic alliances and acquisition among the vendors.”

According to the report, one driver in the market is physician’s preference toward hormonal therapy. The abnormal growth in testosterone level characterizes prostate cancer. Therefore, hormone therapies, which control the secretion of this hormone and help reduce the growth of prostate cancer cells, remain the most sought-after therapy for treating CRPC. The proven efficacious profiles of these therapies with established clinical credentials have led to increased adoption among physicians. Hormonal therapies dominate the global CRPC treatment market and are expected to continue with the same during the forecast period.

Further, the report states that one challenge in the market is high cost of treatment. The high cost of treatment is a major problem for the CRPC patients across the globe. Many of the treatment options available for the individuals are out of their budget and ultimately forces the individual or the payer to skip the treatment. Virtual monopoly among the drug manufacturers and the high cost of R&D are some of the major factors for the high cost of CRPC treatment. A large proportion of population either skip the treatment or leave it in the middle.
Note: Product cover images may vary from those shown
5 of 5
  • Astellas Pharma
  • Johnson & Johnson
  • Sanofi
  • Valeant
  • Active Biotech
  • Advaxis
  • ANI Pharmaceuticals
  • Athenex
  • Bavarian Nordic
  • Bayer
  • Bristol-Myers Squibb
  • CureVac
  • GlaxoSmithKline
  • Innocrin Pharmaceutical
  • Merck
  • Myovant Sciences
  • Northwest Biotherapeutics
  • OncoGenex Pharmaceuticals
  • Oncolytics Biotech
  • Orion
  • Sotio
  • Madrigal Pharmaceuticals
  • Takeda Pharmaceutical
  • Teva Pharmaceutical Industries
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll